Plasma β-amyloid in Alzheimer's disease and vascular disease

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Janelidze, Shorena ^a   Stomrud, Erik ^a,b   Palmqvist, Sebastian ^a,b   Zetterberg, Henrik ^c,d   Van Westen, Danielle ^b,e   Jeromin, Andreas ^f   Song, Linan ^f   Hanlon, David ^f   Tan Hehir, Cristina A ^g   Baker, David ^h   Blennow, Kaj ^c   Hansson, Oskar ^a,b  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e LUND UNIVERSITY   (Sweden)

^f QUANTERIX CORPORATION   (United States)

^g GE GLOBAL RESEARCH   (United States)

^h JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; BIOLOGICAL MARKER;

AGED; ALZHEIMER DISEASE; BLOOD; CEREBROSPINAL FLUID; COHORT ANALYSIS; DIAGNOSTIC IMAGING; FEMALE; GENETICS; HUMAN; MALE; METABOLISM; NEOCORTEX; POSITRON EMISSION TOMOGRAPHY; VASCULAR DISEASE;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; APOLIPOPROTEIN E4; BIOMARKERS; COHORT STUDIES; FEMALE; HUMANS; MALE; NEOCORTEX; POSITRON-EMISSION TOMOGRAPHY; VASCULAR DISEASES;

EID: 84973333119     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep26801     Document Type: Article

References (50)

1. Blennow, K. et al. Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease. Alzheimers Dement 11, 58-69 (2015).
2. Blennow, K., Hampel, H., Weiner, M. & Zetterberg, H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6, 131-144 (2010).
3. Jack, C. R. Jr. et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 12, 207-216 (2013).
4. Bateman, R. J. et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 367, 795-804 (2012).
5. Buchhave, P. et al. Cerebrospinal fluid levels of beta-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 69, 98-106 (2012).
6. Blennow, K., Mattsson, N., Scholl, M., Hansson, O. & Zetterberg, H. Amyloid biomarkers in Alzheimer's disease. Trends Pharmacol Sci 36, 297-309 (2015).
7. Dubois, B. et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol 13, 614-629 (2014).
8. McKhann, G. M. et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 263-269 (2011).
9. Snyder, H. M. et al. Developing novel blood-based biomarkers for Alzheimer's disease. Alzheimers Dement 10, 109-114 (2014).
10. Graff-Radford, N. R. et al. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Archives of neurology 64, 354-362 (2007).
11. Schupf, N. et al. Peripheral Abeta subspecies as risk biomarkers of Alzheimer's disease. Proc Natl Acad Sci USA 105, 14052-14057 (2008).
12. Toledo, J. B. et al. Factors affecting Abeta plasma levels and their utility as biomarkers in ADNI. Acta Neuropathol 122, 401-413 (2011).
13. van Oijen, M., Hofman, A., Soares, H. D., Koudstaal, P. J. & Breteler, M. M. Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol 5, 655-660 (2006).
14. Swaminathan, S. et al. Association of plasma and cortical amyloid beta is modulated by APOE epsilon4 status. Alzheimers Dement 10, e9-e18 (2014).
15. Rembach, A. et al. Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease. Alzheimers Dement 10, 53-61 (2014).
16. Rissin, D. M. et al. Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat Biotechnol 28, 595-599 (2010).
17. Lista, S., Zetterberg, H., Dubois, B., Blennow, K. & Hampel, H. Cerebrospinal fluid analysis in Alzheimer's disease: technical issues and future developments. J Neurol 261, 1234-1243 (2014).
18. American Psychiatric Association. Work Group to Revise DSM-III. Diagnostic and statistical manual of mental disorders: DSM-III-R 3rd edn, (American Psychiatric Association, 1987).
19. McKhann, G. et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944 (1984).
20. Palmqvist, S. et al. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid beta-amyloid 42: a crossvalidation study against amyloid positron emission tomography. JAMA neurology 71, 1282-1289 (2014).
21. Lachno, D. R. et al. Validation of a multiplex assay for simultaneous quantification of amyloid-beta peptide species in human plasma with utility for measurements in studies of Alzheimer's disease therapeutics. J Alzheimers Dis 32, 905-918 (2012).
22. Okereke, O. I. et al. Performance characteristics of plasma amyloid-beta 40 and 42 assays. J Alzheimers Dis 16, 277-285 (2009).
23. Janelidze, S. et al. CSF Aβ 42/Aβ 40 and Aβ 42/Aβ 38 ratios: better diagnostic markers of Alzheimer disease. Annals of Clinical and Translational Neurology (In press).
24. Palmqvist, S. et al. Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. Neurology 85, 1240-1249 (2015).
25. Koole, M. et al. Whole-body biodistribution and radiation dosimetry of 18F-GE067: a radioligand for in vivo brain amyloid imaging. J Nucl Med 50, 818-822 (2009).
26. Lundqvist, R. et al. Implementation and validation of an adaptive template registration method for 18F-flutemetamol imaging data. J Nucl Med 54, 1472-1478 (2013).
27. Wahlund, L. O. et al. A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke; a journal of cerebral circulation 32, 1318-1322 (2001).
28. Gregoire, S. M. et al. The Microbleed Anatomical Rating Scale (MARS): reliability of a tool to map brain microbleeds. Neurology 73, 1759-1766 (2009).
29. Lautner, R. et al. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease. JAMA Psychiatry 71, 1183-1191 (2014).
30. Michaelson, D. M. APOE epsilon4: the most prevalent yet understudied risk factor for Alzheimer's disease. Alzheimers Dement 10, 861-868 (2014).
31. Toledo, J. B. et al. Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. Brain : a journal of neurology 138, 2701-2715 (2015).
32. Hansson, O. et al. Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiol Aging 31, 357-367 (2010).
33. Lewczuk, P. et al. Amyloid beta peptides in plasma in early diagnosis of Alzheimer's disease: A multicenter study with multiplexing. Exp Neurol 223, 366-370 (2010).
34. Mayeux, R. et al. Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk. Neurology 61, 1185-1190 (2003).
35. Hansson, O. et al. Evaluation of plasma Abeta as predictor of Alzheimer's disease in older individuals without dementia: a population-based study. J Alzheimers Dis 28, 231-238 (2012).
36. Pesaresi, M. et al. Plasma levels of beta-amyloid (1-42) in Alzheimer's disease and mild cognitive impairment. Neurobiol Aging 27, 904-905 (2006).
37. van Dijk, E. J. et al. Plasma amyloid beta, apolipoprotein E, lacunar infarcts, and white matter lesions. Ann Neurol 55, 570-575 (2004).
38. Roher, A. E. et al. Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease. Alzheimers Dement 5, 18-29 (2009).
39. Gurol, M. E. et al. Plasma beta-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy. Neurology 66, 23-29 (2006).
40. Paris, D. et al. Vasoactive effects of A beta in isolated human cerebrovessels and in a transgenic mouse model of Alzheimer's disease: role of inflammation. Neurol Res 25, 642-651 (2003).
41. Bell, R. D. & Zlokovic, B. V. Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta Neuropathol 118, 103-113 (2009).
42. Bennett, S. A. et al. Cleavage of amyloid precursor protein elicited by chronic cerebral hypoperfusion. Neurobiol Aging 21, 207-214 (2000).
43. Zetterberg, H. et al. Hypoxia due to cardiac arrest induces a time-dependent increase in serum amyloid beta levels in humans. PLoS One 6, e28263 (2011).
44. Bornebroek, M. et al. Hereditary cerebral hemorrhage with amyloidosis Dutch type (AbetaPP 693): decreased plasma amyloid-beta 42 concentration. Neurobiol Dis 14, 619-623 (2003).
45. Greenberg, S. M. et al. Plasma beta-amyloid peptide, transforming growth factor-beta 1, and risk for cerebral amyloid angiopathy. Ann N Y Acad Sci 903, 144-149 (2000).
46. Hernandez-Guillamon, M. et al. Plasma beta-amyloid levels in cerebral amyloid angiopathy-associated hemorrhagic stroke. Neurodegener Dis 10, 320-323 (2012).
47. Lambert, J. C. et al. Association of plasma Ass peptides with blood pressure in the elderly. PLoS One 6, e18536 (2011).
48. Stamatelopoulos, K. et al. Amyloid-beta (1-40) and the risk of death from cardiovascular causes in patients with coronary heart disease. J Am Coll Cardiol 65, 904-916 (2015).
49. Burnham, S. C. et al. A blood-based predictor for neocortical Abeta burden in Alzheimer's disease: results from the AIBL study. Mol Psychiatry 19, 519-526 (2014).
50. Mapstone, M. et al. Plasma phospholipids identify antecedent memory impairment in older adults. Nature medicine 20, 415-418 (2014).